Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry

Krzysztof Madry; Karol Lis; Pierre Fenaux; David Bowen; Argiris Symeonidis; Moshe Mittelman; Reinhard Stauder; Jaroslav Cermak; Guillermo Sanz; Mette Skov Holm; Agnes Guerci-Bresler; Dominic  Culligan; Laurence Sanhes; Ioannis Kotsianidis; Corine van Marrewijk; Simon Crouch; Theo de Witte; Alexandra Smith

doi:10.1111/bjh.18542

Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry

Krzysztof Madry, Karol Lis, Pierre Fenaux, David Bowen, Argiris Symeonidis , Moshe Mittelman, Reinhard Stauder, Jaroslav Cermak, Guillermo Sanz, Mette Skov Holm, Agnes Guerci-Bresler, Dominic Culligan, Laurence Sanhes, Ioannis Kotsianidis, Corine van Marrewijk, Simon Crouch, Theo de Witte, Alexandra Smith

Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.

Original language	English
Pages (from-to)	451-461
Number of pages	11
Journal	British Journal of Haematology
Volume	200
Issue number	4
Early online date	6 Nov 2022
DOIs	https://doi.org/10.1111/bjh.18542
Publication status	Published - 1 Feb 2023

Access to Document

10.1111/bjh.18542

Cite this

Madry, K., Lis, K., Fenaux, P., Bowen, D., Symeonidis , A., Mittelman, M., Stauder, R., Cermak, J., Sanz, G., Skov Holm, M., Guerci-Bresler, A., Culligan, D., Sanhes, L., Kotsianidis, I., van Marrewijk, C., Crouch, S., de Witte, T., & Smith, A. (2023). Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry. British Journal of Haematology, 200(4), 451-461. https://doi.org/10.1111/bjh.18542

@article{3d0e7afd587e4f3a8f041cae3ba30f9d,

title = "Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry",

abstract = "Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.",

author = "Krzysztof Madry and Karol Lis and Pierre Fenaux and David Bowen and Argiris Symeonidis and Moshe Mittelman and Reinhard Stauder and Jaroslav Cermak and Guillermo Sanz and {Skov Holm}, Mette and Agnes Guerci-Bresler and Dominic Culligan and Laurence Sanhes and Ioannis Kotsianidis and {van Marrewijk}, Corine and Simon Crouch and {de Witte}, Theo and Alexandra Smith",

year = "2023",

month = feb,

day = "1",

doi = "10.1111/bjh.18542",

language = "English",

volume = "200",

pages = "451--461",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

Madry, K, Lis, K, Fenaux, P, Bowen, D, Symeonidis , A, Mittelman, M, Stauder, R, Cermak, J, Sanz, G, Skov Holm, M, Guerci-Bresler, A, Culligan, D, Sanhes, L, Kotsianidis, I, van Marrewijk, C, Crouch, S, de Witte, T & Smith, A 2023, 'Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry', British Journal of Haematology, vol. 200, no. 4, pp. 451-461. https://doi.org/10.1111/bjh.18542

TY - JOUR

T1 - Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry

AU - Madry, Krzysztof

AU - Lis, Karol

AU - Fenaux, Pierre

AU - Bowen, David

AU - Symeonidis , Argiris

AU - Mittelman, Moshe

AU - Stauder, Reinhard

AU - Cermak, Jaroslav

AU - Sanz, Guillermo

AU - Skov Holm, Mette

AU - Guerci-Bresler, Agnes

AU - Culligan, Dominic

AU - Sanhes, Laurence

AU - Kotsianidis, Ioannis

AU - van Marrewijk, Corine

AU - Crouch, Simon

AU - de Witte, Theo

AU - Smith, Alexandra

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.

AB - Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.

U2 - 10.1111/bjh.18542

DO - 10.1111/bjh.18542

M3 - Article

SN - 0007-1048

VL - 200

SP - 451

EP - 461

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -